Home / Medications / Compare Drugs / Gemtesa vs Myrbetriq

Gemtesa vs Myrbetriq

Drug facts and comparison

✅
Medically reviewed by  Jamie Winn, PharmD

Uses

  • Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults
Get Gemtesa for only
$49 per month
Get started
  • Treatment of an overactive bladder in adults
Get Myrbetriq for only
$49 per month
Get started

Summary

Brand name: Gemtesa
Brand name: Myrbetriq
Manufacturer: Urovant Sciences, Inc.
Manufacturer: Astellas Pharma US, Inc
Active ingredient: vibegron
Active ingredient: mirabegron
Indication: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults
Indication: Treatment of an overactive bladder in adults

Side Effects

Most common

  • Headache
  • Urinary tract infection
  • Upper respiratory tract infection
  • Nasopharyngitis
  • Runny nose
  • Sore throat
  • Diarrhea
  • Nausea

More serious

  • Urinary retention

Most common

  • Increased heart rate
  • Nausea
  • Headaches
  • Constipation
  • Diarrhea
  • Dizziness
  • Urinary tract infections

More serious

  • Irregular heartbeat (atrial fibrillation)
  • Severe rise in blood pressure (hypertensive crisis)

Drug Interactions

Severe interactions
  • No severe interactions
Serious interactions
  • Cardiac glycosides – digoxin
  • Treatments for overactive bladder – fesoterodine, oxybutynin, solifenacin, tolterodine, trospium
Moderate interactions
  • No moderate interactions
Severe interactions
  • Treatment for hereditary angioedema-HAE – berotralstat
  • Treatment for Gaucher disease type 1 eliglustat
  • Treatment for breast cancer – tamoxifen
Serious interactions
  • Antidepressants – amitriptyline, nortriptyline
  • Antipsychotics – clozapine, haloperidol
  • Opioids – codeine
  • Beta-blockers – propranolol
  • HIV protease inhibitors – ritonavir
Moderate interactions
  • Antiarrhythmics – amiodarone, dronedarone
  • Antifungals – clotrimazole, ketoconazole, itraconazole
  • Seizure medications – carbamazepine,  phenobarbital, phenytoin
  • Antibiotics – clarithromycin, erythromycin
  • Immunosuppressants – cyclosporine
  • Anticoagulants – warfarin

Warnings

You should not use Gemtesa if you:

  • Are allergic to the active ingredient vibegron
  • Have had an allergic reaction to any of the other ingredients in Gemtesa
  • Are pregnant or are planning to become pregnant

You should talk to your doctor before using Gemtesa if you:

  • Are taking any of the medications that could interact with Gemtesa
  • Have end-stage renal disease with or without hemodialysis
  • Have severe hepatic impairment
  • Are breastfeeding or are planning to breastfeed

You should not use Myrbetriq if you:

  • Are allergic to the active ingredient mirabegron
  • Are allergic to any of the other ingredients in Myrbetriq
  • If you have high blood pressure that is not controlled
  • Are under 18 years of age
  • Are pregnant or are planning to become pregnant

You should talk to your doctor before using Myrbetriq if you:

  • Take any other medications for an overactive bladder
  • Have trouble emptying your bladder or have a weak urine stream
  • Have any liver or kidney problems
  • Have an ECG (heart tracing) abnormality called QT prolongation
  • Are breastfeeding or are planning to breastfeed

Dosage

Once daily

Based on the condition treated and body weight

Cost

30, 75 mg Gemtesa tablets 75 mg will cost around $490

30, 50 mg Myrbetriq tablets will cost around $540

FAQs

Overactive bladder (OAB) is a common condition causing urinary urgency, frequency, and leakage. The key symptom is the sudden desire to urinate that is difficult to suppress. Historically, anticholinergics and antimuscarinics have been used to treat overactive bladder (OAB). However, these therapies have been shown to have side effects, such as dry mouth, drowsiness, constipation, dizziness, and confusion, as well as an increase in the risk of cognitive impairment and dementia.

Gemtesa and Myrbetriq are prescription drugs used for the treatment of overactive bladder. Here we will explain how they work, their similarities and differences, their side effects, and more. This should provide you with the basics to better understand your options.

What is Gemtesa?

Gemtesa is manufactured by Urovant Sciences, Inc. It has FDA approval (U.S. Food and Drug Administration) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, incontinence episodes, and urinary frequency in adults.

Vibegron is a beta-3 adrenergic agonist that works by relaxing a certain bladder muscle (detrusor, a smooth muscle in the wall of the bladder) which helps to increase bladder capacity and lessens symptoms of overactive bladder.

Gemtesa dosage

Gemtesa is available in tablet form, in the following doses: 75 mg.

The recommended dose is one 75 mg tablet once daily. Swallow the tablet whole with a full glass of water, with or without food. Tablets may be crushed and mixed with applesauce.

Always speak with a healthcare professional for medical advice about any changes to your dose so they can monitor and evaluate your condition.

What is Myrbetriq?

Myrbetriq is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Astellas Pharma US, Inc. Myrbetriq is also a prescription medication used to treat OAB symptoms in adults. Myrbetriq helps relax your bladder muscles, providing relief from the symptoms of an overactive bladder.

The active ingredient in Myrbetriq is called mirabegron. Mirabegron relaxes the muscles in the wall of your bladder (detrusor urinae muscle) to reduce the symptoms of an overactive bladder. It does this by attaching itself to areas on the surface of the muscles called β3-adrenergic receptors. These receptors are stimulated by mirabegron, starting a process that relaxes the bladder muscles.

Myrbetriq dosage

Myrbetriq is available in extended-release tablet form, in the following doses: 25 mg and 50 mg.

The recommended starting dose is 25 mg once daily, alone or in combination with solifenacin succinate 5 mg, once daily. The dose may be increased to 50 mg once daily. Swallow the tablets whole with water, with or without food, do not chew, divide or crush. For patients with severe renal or hepatic impairment, the maximum dose is 25 mg once daily.

Common side effects of Gemtesa and Myrbetriq

The most common side effects of Gemtesa in clinical trials compared to placebo include:

  • Headache
  • Urinary tract infection
  • Upper respiratory tract infection
  • Nasopharyngitis
  • Runny nose
  • Sore throat
  • Diarrhea, nausea

More serious side effects of Gemtesa include:

  • Urinary retention

The most common side effects of Myrbetriq in clinical trials compared to placebo include:

  • increased heart rate (tachycardia)
  • Nausea
  • Headaches
  • Constipation
  • Diarrhea
  • Dizziness
  • Increased risk of urinary tract infections

More serious side effects of Myrbetriq include

  • Irregular heartbeat
  • Severe rise in blood pressure (hypertension)

These aren’t all the side effects Gemtesa or Myrbetriq can cause. You can find more details in the patient leaflet that comes with your medication. If you have any concerns about adverse effects, talk to your physician or pharmacist.

Gemtesa and Myrbetriq drug interactions

Gemtesa can interact with other medications. These include:

  • Digoxin

Myrbetriq can interact with other medications. These include:

  • Treatments for depression or other mental health illnesses
  • Digoxin
  • Other medications for an abnormal heart rhythm
  • Antipsychotic medicines

Gemtesa and Myrbetriq can interact with other medications. This can change how Gemtesa and Myrbetriq and other medications work and can make side effects more likely. Tell your prescribing physician about all your drugs, including vitamins and dietary supplements.

Gemtesa and Myrbetriq contraindications

You should not use Gemtesa if you:

  • Are allergic to the active ingredient vibegron
  • Have had an allergic reaction to any of the other ingredients in Gemtesa
  • Are pregnant or are planning to become pregnant

Talk to your doctor about your medical condition before using Gemtesa if you:

  • Are taking any of the medications that could interact with Gemtesa
  • Have end-stage renal disease with or without hemodialysis
  • Have severe hepatic impairment (liver problems)
  • Are breastfeeding or are planning to breastfeed

You should not use Myrbetriq if you:

  • Are allergic to the active ingredient mirabegron
  • Are allergic to any of the other ingredients in Myrbetriq (listed in the leaflet which comes with the medication)
  • If you have high blood pressure that is not controlled
  • Are under 18 years of age
  • Are pregnant or trying to become pregnant

Talk to your physician before taking Myrbetriq if you:

  • Take any other medications for an overactive bladder
  • Have trouble emptying your bladder or have a weak urine stream
  • Have any liver or kidney problems
  • Have an ECG (heart tracing) abnormality called QT prolongation
  • Are breastfeeding or plan to breastfeed

Other drugs for an overactive bladder

  • Toviaz (fesoterodine)
  • Detrol (tolterodine)
  • Vesicare (solifenacin)
  • Ditropan (oxybutynin)

If you have any concerns about Gemtesa or Myrbetriq side effects, talk to your physician, or pharmacist for medical advice. Also inform your healthcare provider about any medical conditions, supplements, and over-the-counter meds you are taking. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.
NiceRx Logo

Your medication,
$49 per month

Get your medication for only $49 per month through NiceRx.

Get Started